This new report by Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the European skin replacements and substitutes and active wound repair modulators market. Major topics covered by this report include an overview of the healthcare markets of France, Germany, Italy, Spain, and the United Kingdom; an overview of clinical issues in wound management; skin replacement and substitutes including allografts, autografts, xenografts, amniotic membranes, and autologous and tissue-engineered skin replacements and substitutes (e.g., epidermal, dermal, and composite bilayer skin equivalents); and active wound repair modulators including topical antimicrobials, growth factors, gene therapy agents, antibiotics/anti-infectives, hormones, matrix metalloproteinase enzyme inhibitors, neuropeptides, and stem cells.
EXECUTIVE SUMMARY i. Clinical Issues in Wound Management ii. Skin Replacements and Substitutes a. Allografts b. Autografts c. Xenografts d. Amniotic Membranes e. Skin Equivalents f. Skin Replacements and Substitutes, Market Analysis iii. Active Wound Repair Modulators a. Topical Antimicrobial Products b. Growth Factors c. Other Active Wound Repair Modulators d. Active Wound Repair Modulators, Market Analysis iv. Combined Market Analysis a. Market Drivers b. Market Limiters c. Combined Market Forecast Exhibit ES-1: Europe, Skin Replacements and Substitutes, Market Forecast, by Country, 2008-2013 Exhibit ES-2: Europe, Active Wound Repair Modulators, Market Forecast, by Country, 2008-2013 Exhibit ES-3: Europe, Skin Replacements and Substitutes and Active Wound Repair Modulators, Combined Market Forecast, by Country, 2008-2013 1. EUROPEAN HEALTHCARE MARKETS 1.1 The European Union 1.1.1 A Common Currency 1.1.2 Regulatory Policies 1.1.3 Reimbursement 1.1.4 Healthcare Spending 1.2 Selected European National Healthcare Profiles 1.2.1 France 184.108.40.206 Healthcare Organization and Reform 220.127.116.11 Hospital Services 18.104.22.168 Medical Device Reimbursement 1.2.2 Germany 22.214.171.124 Healthcare Organization and Reform 126.96.36.199 Hospital Services 188.8.131.52 Medical Device Reimbursement 1.2.3 Italy 184.108.40.206 Healthcare Organization and Reform 220.127.116.11 Hospital Services 18.104.22.168 Medical Device Reimbursement 1.2.4 Spain 22.214.171.124 Healthcare Organization and Reform 126.96.36.199 Hospital Services 188.8.131.52 Medical Device Reimbursement 1.2.5 United Kingdom 184.108.40.206 Healthcare Organization and Reform 220.127.116.11 Hospital Services 18.104.22.168 Medical Device Reimbursement Exhibit 1-1: European Union, Medical Devices Risk Classification System Exhibit 1-2: European Union Population Statistics Comparison for the Years 1999, 2009, and 2019 Exhibit 1-3: France, Selected National Healthcare Statistics Exhibit 1-4: Germany, Selected National Healthcare Statistics Exhibit 1-5: Italy, Selected National Healthcare Statistics Exhibit 1-6: Spain, Selected National Healthcare Statistics Exhibit 1-7: United Kingdom, Selected National Healthcare Statistics 2. CLINICAL ISSUES IN WOUND MANAGEMENT 2.1 Physiology of Wound Closure 2.1.1 Layers of the Skin and Supporting Structures 22.214.171.124 Epidermis 126.96.36.199 Dermis 188.8.131.52 Subcutaneous Tissue 184.108.40.206 Fascia 220.127.116.11 Muscle 18.104.22.168 Bone 2.1.2 Wound Closure Process 22.214.171.124 Hemostasis 126.96.36.199 Inflammation 188.8.131.52 Proliferation 184.108.40.206 Remodeling Phase 2.2 Factors Affecting Wound Closure 2.2.1 Extrinsic Factors 220.127.116.11 Desiccation 18.104.22.168 Hydration 22.214.171.124 Infection 126.96.36.199 Maceration 188.8.131.52 Medication and Other Treatment Modalities 184.108.40.206 Necrotic Tissue and Debris 220.127.116.11 Oxygenation 18.104.22.168 Stress 22.214.171.124 Temperature 126.96.36.199 Wound Creation and Depth 188.8.131.52 Wound Closure Techniques 184.108.40.206 Other Extrinsic Factors 2.2.2 Intrinsic Factors 220.127.116.11 Body Build 18.104.22.168 Chronic Illness and Age 22.214.171.124 Nutrition 2.2.3 Complications of Wound Healing 126.96.36.199 Bleeding 188.8.131.52 Scarring 2.3 Major Wound Types 2.3.1 Amputation 2.3.2 Arterial Ulcers 2.3.3 Burns 2.3.4 Diabetic Ulcers 2.3.5 Pressure Ulcers 2.3.6 Surgical Wounds 2.3.7 Traumatic Wounds 2.3.8 Venous Ulcers Exhibit 2-1: The Skin's Layers and Supporting Structures Exhibit 2-2: Phases of the Wound Closure Process Exhibit 2-3: Extrinsic and Intrinsic Factors Affecting Wound Closure Exhibit 2-4: Major Wound Types, by Cause Exhibit 2-5: Stages of Burn Wounds Exhibit 2-6: Stages of Pressure Ulcers Exhibit 2-7: 2008, Europe, Surgical Procedure Volumes, by Type 3. SKIN REPLACEMENTS AND SUBSTITUTES MARKET 3.1 Allografts 3.2 Autografts 3.3 Xenografts 3.4 Amniotic Membranes 3.5 Autologous and Tissue-Engineered Skin Replacements and Substitutes 3.5.1 Epidermal Equivalents 3.5.2 Dermal Equivalents 3.5.3 Composite Bilayer Skin Equivalents 3.6 Skin Substitute Products under Development 3.6.1 Advanced BioHealing 3.6.2 Healthpoint/DFB Pharmaceuticals 3.6.3 Organogenesis 3.6.4 Dr. Suwelack Skin & Health Care 3.7 Market Analysis 3.8 Competitive Analysis Exhibit 3-1: Advantages and Disadvantages of Allografts Exhibit 3-2: 2010, Selected Epidermal Equivalent Skin Substitutes Exhibit 3-3: 2010, Selected Dermal Equivalent Skin Substitutes Exhibit 3-4: 2010, Selected Composite Bilayer Equivalent Skin Substitutes Exhibit 3-5: Europe, Skin Replacements and Substitutes, Market Forecast, by Country, 2008-2013 Exhibit 3-6: 2009, Europe, Skin Replacements and Substitutes Market, Share by Supplier 4. ACTIVE WOUND REPAIR MODULATORS MARKET 4.1 Topical Antimicrobials 4.1.1 Products 4.1.2 Market Analysis 4.1.3 Competitive Analysis 4.2 Growth Factors 4.2.1 Classification of Growth Factors 184.108.40.206 Fibroblast Growth Factors 220.127.116.11 Transforming Growth Factors 18.104.22.168 Epidermal Growth Factors 22.214.171.124 Platelet-Derived Growth Factors 126.96.36.199 Insulin-Like Growth Factors 188.8.131.52 Keratinocyte Growth Factors 184.108.40.206 Vascular Endothelial Growth Factors 220.127.116.11 Autologous Growth Factors 18.104.22.168.1 Arteriocyte Medical Systems 22.214.171.124.2 Cytomedix 126.96.36.199.3 Harvest Technologies 188.8.131.52 Angiogenic Growth Factors 4.2.2 Products 4.2.3 Market Analysis 4.3 Gene Therapy Agents 4.4 Other Active Wound Repair Modulators 4.4.1 Antibiotics and Anti-Infectives 184.108.40.206 Basilea Pharmaceutica 220.127.116.11 Cerexa/Forest Laboratories 18.104.22.168 Cubist Pharmaceuticals 22.214.171.124 Helix BioMedix 126.96.36.199 Theravance 4.4.2 Hormones 4.4.3 Matrix Metalloproteinase Enzyme Inhibitors 188.8.131.52 Dermagenics/Greystone Pharmaceuticals 184.108.40.206 Smith & Nephew 220.127.116.11 Systagenix Wound Management 4.4.4 Neuropeptides in Diabetic Wounds 4.4.5 Stem Cells 4.4.6 Other Products 18.104.22.168 Kingfisher Healthcare 22.214.171.124 Pioneer Surgical Orthobiologics/Pioneer Surgical Technology 126.96.36.199 RegeneRx Biopharmaceuticals Exhibit 4-1: 2010, Selected Topical Antimicrobial Products Exhibit 4-2: Europe, Topical Antimicrobial Products, Market Forecast, by Country, 2008-2013 Exhibit 4-3: 2009, Europe, Topical Antimicrobial Products, Share by Supplier Exhibit 4-4: 2010, Selected Growth Factors in Development for Wound Healing Applications Exhibit 4-5: 2010, Selected Angiogenic Growth Factors Exhibit 4-6: Europe, Growth Factors Used in Wound Healing Applications, Market Forecast, by Country, 2008-2013 5. COMPANY PROFILES 5.1 Advanced BioHealing, Inc. 5.2 Cook Biotech, Inc./Cook Group, Inc. 5.3 Cytomedix, Inc. 5.4 Fidia Advanced Biopolymers SRL/Anika Therapeutics, Inc. 5.5 GlaxoSmithKline PLC 5.6 Integra LifeSciences Corporation 5.7 LEO Pharma AS/LEO Foundation 5.8 sanofi-aventis 5.9 Smith & Nephew PLC 5.10 Systagenix Wound Management LTD APPENDIX: COMPANY LISTING